Corvus Pharmaceuticals initiated phase 3 clinical trial of CPI-006 for patients with COVID-19
On Feb. 4, 2021, Corvus Pharmaceuticals announced that it had initiated a Phase 3 clinical trial of CPI-006…
COVAX expected to start sending millions of COVID-19 vaccines to Africa in February
On Feb. 4, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
Oxford Immunotec updated T-SPOT Discovery SARS-CoV-2 kit to detect T Cells reactive to endemic Coronaviruses
On Feb. 4, 2021, Oxford Immunotec announced an update to the configuration of the T-SPOT Discovery SARS-CoV-2 kit….
The US Department of Defense announced use of masks and other public health measures
On Feb. 4, 2021, the U.S. Department of Defense Secretary of Defense directed all individuals on military installations…
Novavax announced start of rolling review by multiple regulatory authorities for COVID-19 vaccine authorization
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
Johnson & Johnson announced submission of application to FDA for EUA of its single-shot COVID-19 vaccine candidate
On Feb. 4, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, had submitted an application to the…
COVAX expected to start sending millions of COVID-19 vaccines to Africa in February
On Feb. 3, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
XPhyto announced psychedelic pharmaceutical production agreement
On Feb. 3, 2021, XPhyto announced an agreement with Applied Pharmaceutical Innovation for the synthesis of pharmaceutical grade…
Vaxart announced positive preliminary data from phase 1 clinical trial evaluating oral COVID-19 tablet vaccine candidate
On Feb. 3, 2021, Vaxart announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its…
AXIM Biotechnologies began clinical trials of ImmunoPass rapid diagnostic test with vaccine recipients
On Feb. 3, 2021, AXIM Biotechnologies announced initiation of clinical trials for ImmunoPass, the Companyï¾’s rapid point-of-care test…
Quidel opens new manufacturing facility to mass produce QuickVue Rapid Antigen Tests for COVID-19
On Feb. 3, 2021, Quidel announced the opening of a new manufacturing facility in Carlsbad, CA that was…
Dynavax and Serum Institute announced first participant dosed in trial evaluating Tdap vaccine adjuvanted with CpG 1018
On Feb. 3, 2021, Dynavax Technologies and Serum Institute of India announced that the first participant has been…
First-in-human clinical trial confirmed novel HIV vaccine approach
On Feb. 3, 2021, IAVI and Scripps Research announced a phase 1 clinical trial testing a novel vaccine…
Humanigen and Avid Bioservices entered Into cGMP manufacturing agreement for COVID-19 therapeutic
On Feb. 3, 2021, Avid Bioservices and Humanigen announced that they had entered into a manufacturing services agreement…
Moderna announced amendment to supply agreement with Switzerland for additional 6 million doses of COVID-19 vaccine
On Feb. 3, 2021, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 7.5…
Singapore Health Sciences Authority approved interim authorization of COVID-19 Vaccine Moderna
On Feb. 3, 2021, Moderna announced that the Singapore Health Sciences Authority (HSA) had approved the interim authorization…
Novavax and Government of Switzerland announce agreement in principle to supply COVID-19 vaccine
On Feb. 3, 2021, Novavax announced that the company had executed a binding Heads of Terms agreement with…
NIH study sIntranasal influenza vaccine spurred strong immune response in Phase 1 study
On Feb. 3, 2021, an experimental single-dose, intranasal influenza vaccine, was safe and produced a durable immune response…
BD announced assay for identification of COVID-19 patients at increased risks of intubation available in Europe
On Feb. 3, 2021, BD (Becton, Dickinson) announced the CE mark of BD Multitestï¾™ 6-Color TBNK Reagent with…
Bristol Myers and Rockefeller University announced license agreement for SARS-CoV-2 meutralizing mAb combination
On Feb. 3, 2021, Bristol-Myers and The Rockefeller University announced an agreement under which Bristol Myers Squibb was…
NeuroRx initiated phase 2/3 study of inhaled ZYESAMI for severe COVID-19 with UCI Health
On Feb. 3, 2021, RELIEF THERAPEUTICS affirmed that its collaboration partner NeuroRx had initiated a phase 2/3 clinical…
GSK and CureVac announced JV to develop next generation mRNA COVID-19 vaccines
On Feb. 2, 2021, GlaxoSmithKline and CureVac announced a new ï¾€150m collaboration, building on their existing relationship, to…
Mateon announced completion of ARTI-19 and publication of positive interim data
On Feb. 2, 2021, Mateon Therapeutics announced that its ARTI-19 trial, evaluating ARTIVeda / PulmoHeal against COVID-19 in…
SARS-CoV-2 spike protein licensed by Oragenics from the NIH demonstrated protective immunity in mice
On Feb. 2, 2021, Oragenics announced that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National…
VBI Vaccines announced FDA Acceptance of BLA filing for VBIï¾’s 3-antigen prophylactic hepatitis B vaccine
On Feb. 2, 2021, VBI Vaccines announced that the FDA had accepted its filing of the Biologics License…
Novavax announced MOU to produce COVID-19 vaccine made in Canada
On Feb. 2, 2021, Novavax announced a memorandum of understanding with the Canadian government to produce NVX-CoV2373, the…
Roche announced launch of SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection
On Feb. 1, 2021, Roche announced it had obtained the CE mark for its new SARS-CoV-2 Rapid Antigen…
NIH study showed hyaluronan effective in treating chronic lung disease
On Feb. 1, 2021, researchers at the National Institutes of Health and their collaborators found that inhaling unfragmented…
Clover and Dynavax announced planned global phase 2/3 efficacy trial of adjuvanted COVID-19 vaccine candidate
On Feb. 1, 2021, Clover Biopharmaceuticals and Dynavax Technologies announced a plan to initiate a global Phase 2/3…
Dynavax and CEPI announced $99 million in funding for CpG 1018 adjuvant manufacturing
On Feb. 1, 2021, Dynavax Technologies and the Coalition for Epidemic Preparedness Innovations (CEPI) announced they have entered…